title: [Treatment of acute alcoholic alcoholism].
abstract: Acute alcoholic hepatitis is the first alcoholic lesion of the liver in the process of progression to cirrhosis. It is due to the toxic action of alcohol on hepatocytes, in particular in the centrolobular region. It may affect a liver which is the site of fatty infiltration, fibrosis or cirrhosis, i.e. during all the stages of alcoholic liver disease. Its severity depends upon the degree of alcoholic intoxication. It may be fatal by malignant hepatic failure in a quarter of cases or, at the extreme, be totally asymptomatic. The aims of treatment are: 1) in the immediate, to prevent death; 2) subsequently, to prevent progression to cirrhosis. The majority of the wide range of treatments suggested have been evaluated in controlled trials. It is thus easy to show that corticosteroids are effective in severe acute alcoholic hepatitis, i.e. with encephalopathy and coagulation disturbances, but no in ordinary forms. Although logical, nutritional supplements, whether enteral or parenteral, have no influence on the course of acute alcoholic hepatitis. The same applies to anabolic steroids, the association insulin-glucagon, antifibrosis agents or "hepatoprotectors". The elimination of alcoholic intoxication remains the most important point, accepted by all hepatologists.
authors.affiliation: Service d'Hépato-gastroentérologie, Institut des Maladies de l'Appareil Digestit, Hôpital Saint-Eloi, Montpellier.
authors.forename: H
authors.initials: H
authors.lastname: Michel
authors.forename: D
authors.initials: D
authors.lastname: Larrey
authors.forename: P
authors.initials: P
authors.lastname: Blanc
mesh_terms: D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D000818:Animals; D013956:Antithyroid Agents / Q000627:therapeutic use; D002392:Catechin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003078:Colchicine / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004750:Enteral Nutrition / Q000379:methods / Q000592:standards; D005934:Glucagon / Q000627:therapeutic use; D006519:Hepatitis, Alcoholic / Q000150:complications / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008104:Liver Cirrhosis, Alcoholic / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D016031:Liver Transplantation / Q000592:standards; D010289:Parenteral Nutrition, Total / Q000379:methods / Q000592:standards; D010396:Penicillamine / Q000627:therapeutic use; D051381:Rats; D012838:Silymarin / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D045930:Anabolic Agents; D013956:Antithyroid Agents; D007328:Insulin; D012838:Silymarin; D002392:Catechin; D005934:Glucagon; D010396:Penicillamine; D003078:Colchicine
vernacular_title: Le traitement de l'hépatite alcoolique aiguë.